<DOC>
	<DOCNO>NCT00961142</DOCNO>
	<brief_summary>Feasibility toxicity haploidentical allogeneic HCT reduce intensity condition regimen CD3/CD19 deplete graft . This study enroll patient acute leukemia complete remission indication allogeneic HCT without suitable HLA-identical donor</brief_summary>
	<brief_title>Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion Reduced Intensity Conditioning Patients With Acute Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Patients either ALL AML CR indication allogeneic HCT accord follow criterion : AML : high risk patient one follow risk factor : FLT3 mutation Complex cytogenetics abn ( 3q ) , 5/5q , 7/7q , abn ( 12p ) , abn ( 17p ) Late CR &gt; induction I Age &gt; 60 Patients 2.CR Secondary AML Relapse precede allogeneic HCT HLAidentical donor ALL : high risk patient one follow risk factor : ProBALL Initial WBC &gt; 30.000/ÂµL CR day 46 Induction II Complex cytogenetics , ( 9,22 ) , ( 4,11 ) Early mature TALL Initially refractory patient late CR Rising MRD level Patients 2 . CR Relapse precede allogeneic HCT HLAidentical donor No HLAidentical donor ( 1 antigen mismatch ( 9/10Match ) 2 allelic mismatch highresolution type ) . Critical case discuss PI . Age &lt; =65 , &gt; =18 year Karnofsky Index &gt; 60 % Patients &gt; 5 % blast BM time transplantation Less 3 month precede HCT CNS involvement disease History neurologic impairment : seizure , severe peripheral neuropathy , sign leukoencephalopathy , CNS infection , multiple intrathecal chemotherapy , CNS irradiation . In case heavy pretreatment irradiation intrathecal chemotherapy pretransplant CNS MRI neurological consultation mandatory Fungal infection radiological progression receipt amphotericin B active triazole great 1 month . Liver function abnormality bilirubin &gt; 2 mg/dL elevation transaminases high 2x upper limit normal . Chronic active viral hepatitis Ejection fraction &lt; 40 % echocardiography Patients &gt; grade II hypertension CTC criterion Creatinine clearance &lt; 50 ml/min Respiratory failure necessitate supplemental oxygen DLCO &lt; 30 % Allergy murine antibody HIVInfection Female patient pregnant breast feeding , adult reproductive potential employ effective method birth control study treatment least 12 month thereafter . ( Women childbearing potential must negative serum pregnancy test study entry ) Concurrent severe and/or uncontrolled medical disease ( e.g . uncontrolled diabetes , congestive heart failure , myocardial infarction within 6 month prior study , unstable uncontrolled hypertension , chronic renal disease , active uncontrolled infection ) could compromise participation study Patients history psychiatric illness condition could interfere ability understand requirement study ( include alcoholism/drug addiction ) Patients unwilling unable comply protocol Unable give inform consent Enrollment trial interfere endpoint study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Haploidentical Transplantation</keyword>
	<keyword>CD3/CD19 Depletion</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>Reduced Intensity Conditioning</keyword>
</DOC>